E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cystic Fibrosis with Mild Lung Disease and P. aeruginosa (AIR-CF4) |
|
E.1.1.1 | Medical condition in easily understood language |
Cystic Fibrosis with Mild Lung Disease and infection with the P. aeruginosa (AIR-CF4) bacteria. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess the safety and efficacy of a 28-day course of AZLI in patients with CF, mild lung disease (FEV1 > 75% predicted), and PA. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients ≥ 6 years of age.
2. Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
a. Sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT);
b. Two well-characterized mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene; or
c. Abnormal nasal potential difference.
3. PA present in expectorated sputum or throat swab culture at Visit 1 OR documented PA in 2 expectorated sputum or throat swab cultures within the 12 months prior to Visit 1. (One of the previous PA positive cultures must be no more than 3 months prior to Visit 1.)
4. FEV1 > 75% predicted at Visit 1.
5. Patient must exhibit two or more of the following chronic and/or intermittent CF symptoms, for a minimum of 28 days prior to randomization and with no worsening of symptoms within 7 days prior to randomization:
a. Chest congestion
b. Daily cough
c. Productive cough
d. Wheezing
e. Trouble breathing
f. Nocturnal wakening due to coughing
6. Patients (and parent/guardian as required) must be able to provide written informed consent/assent prior to any study related procedures.
7. Females of childbearing potential must have a negative urine pregnancy test at Visit 1.
8. Ability to perform reproducible pulmonary function tests.
9. In the opinion of the Investigator, the patient does not require immediate antipseudomonal antibiotic intervention to treat an impending exacerbation, and the patient’s condition is stable enough to enroll in the study. |
|
E.4 | Principal exclusion criteria |
1. Administration of any investigational drug or device within 28 days prior to Visit 1 or within 6 half-lives of the investigational drug (whichever is longer).
2. Administration of any IV, oral, or inhaled antipseudomonal antibiotic within 28 days prior to Visit 1.
3. Known local or systemic hypersensitivity to monobactam antibiotics.
4. Inability to tolerate short-acting bronchodilator use at least three times daily.
5. Changes in or initiation of chronic azithromycin treatment within 28 days prior to Visit 1.
6. Changes in or initiation of chronic hypertonic saline treatment within 28 days prior to Visit 1.
7. Changes in or initiation of dornase alpha within 28 days prior to Visit 1.
8. Changes in antimicrobial, bronchodilator (BD), or corticosteroid medications within 7 days prior to Visit 1.
9. Changes in physiotherapy technique or schedule within 7 days prior to Visit 1.
10. History of lung transplantation.
11. History of participation (enrollment) in any prior clinical trials with AZLI.
12. A chest radiograph at Visit 1 (or within the previous 180 days of Visit 1), with abnormalities indicating a significant acute finding (e.g., lobar infiltrate and atelectasis, pneumothorax, or pleural effusion). A chest radiograph obtained and interpreted between Visits 1 and 2 is also acceptable for determining eligibility.
13. Positive urine pregnancy test at Visit 1; all women of childbearing potential will be tested.
14. Females of childbearing potential who are lactating or are not (in the opinion of the investigator) practicing an acceptable method of birth control; female patients who utilize hormonal contraceptives as their birth control method must have used the same method
for at least 3 months before study dosing.
15. Patient is being assessed at Visit 1 by the investigator for an acute change in respiratory symptoms.
16. Any serious or active medical or psychiatric illness, which in the opinion of the investigator, would interfere with patient treatment, assessment, or compliance with the protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is change from baseline at Day 28 in clinical symptoms as assessed by the respiratory symptoms domain of the CFQ-R. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Change from baseline in clinical symptoms as assessed by the respiratory symptoms
domain of the CFQ-R at Days 14 and 42.
• Change from baseline in clinical symptoms as assessed by the non-respiratory domains of
the CFQ-R at Day 28.
• Use of additional (non-protocol specified) antipseudomonal antibiotics during the course
of the study.
• Proportion of patients hospitalized and the number of days patients were hospitalized
during the study.
• Change from baseline in PA colony-forming units (CFUs) in sputum at Day 28.
• Relative change from baseline FEV1 percent of predicted at Day 28. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Australia |
Canada |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |